RCOR Renovacor, Inc.

Renovacor, Inc., an early-stage biotechnology company, engages in developing a pipeline of adeno-associated virus (AAV) based gene therapies for Bcl2-associated athanogene 3 (BAG3) associated diseases. Its lead program is recombinant AAV-based gene therapy for patients suffering from dilated cardiomyopathy (DCM) due to mutations in the BAG3 gene; and REN-001, an AAV9-based gene therapy to treat BAG3-associated DCM. The company was incorporated in 2013 and is based in Greenwich, Connecticut.

$3.20
As of 11/30/2022     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  
IPO date:  06/22/2020
Outstanding shares:  17,269,415
Average volume:  14,313
Market cap:   $55,262,128
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%